Fatal Submassive Hepatic Necrosis Associated with Tyrosine‐Methionine‐Aspartate‐Aspartate–Motif Mutation of Hepatitis B Virus after Long‐Term Lamivudine Therapy
Open Access
- 1 August 2001
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (3) , 403-405
- https://doi.org/10.1086/321879
Abstract
We present a case of infection with lamivudine-resistant mutant hepatitis B virus (HBV) that fatally exacerbated hepatitis following the emergence of HBV with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif in an immunocompetent patient who was receiving long-term lamivudine therapy. Restriction fragment length polymorphism analysis showed that the YMDD-motif mutant was the predominant form of circulating HBV at the time of the fatal exacerbation, and a necropsy specimen of the liver revealed submassive hepatic necrosis without steatosis.Keywords
This publication has 9 references indexed in Scilit:
- Effects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology, 2000
- Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutantsHepatology, 2000
- Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipientGut, 2000
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft lossJournal of Hepatology, 1998
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyHepatology, 1998
- Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantationThe Lancet, 1997
- Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis BNew England Journal of Medicine, 1995